• Home
  • Search
  • Perturbing resistance: a network perspective.
  • Open Access IconOpen Access
  • Cite Icon1
  • https://doi.org/10.1111/pcmr.12431Copy DOI Icon

Perturbing resistance: a network perspective.

Show More
  • Abstract
  • Literature Map
  • References
  • Citations
  • Similar Papers
Abstract

The recent convergence of high-dimensional molecular datasets with small-molecule inhibitor pipelines allows for selective targeting of aberrantly regulated pathways in many cancer types. But intra-tumor heterogeneity, paradoxical activation, intrinsic or acquired therapeutic resistance, and non-linear pathway interactions confound most simple targeting strategies(Widmer et al., 2015). For instance, MAPK signaling is activated by hot-spot mutations in BRAF, which are found in about 40-50% of melanoma cases. This article is protected by copyright. All rights reserved.

Similar Papers
  • Research Article

Abstract 3589: Targeting metabolic reprogramming and OXPHOS as a viable anti-melanoma strategy

  • Jul 01, 2019
  • Cancer Research
  • Gang Cheng +4
  • Research Article
  • Citations10

Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines.

  • Dec 01, 2021
  • Cancers
  • Vikas Patel +4
  • Research Article

Abstract 4747: Surviving skills in melanoma cells: An important consideration to both targeted and immunological approach in the treatment of melanoma

  • Jul 01, 2019
  • Cancer Research
  • Niramol Savaraj +6
  • Research Article
  • Citations121

BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells

  • Jul 06, 2017
  • Proceedings of the National Academy of Sciences
  • Taral R Lunavat +10
  • PDF
  • Research Article

The effects of aranose, cisplatin or paclitaxel in monotherapy and in combination on the expression of Pd–l1 and Pd–l2 in melanoma cells

  • Jan 11, 2019
  • Russian Journal of Biotherapy
  • A A Rudakova +5
  • Research Article
  • Citations15

Functional consequence of variation in melanoma antigen expression.

  • Oct 01, 1983
  • Cancer Immunology, Immunotherapy
  • Lee M Zehngebot +5
  • Research Article
  • Citations207

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer

  • Jul 21, 2016
  • Cell Reports
  • Alison M Kurimchak +15
  • Research Article
  • Citations18

The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma.

  • Sep 05, 2018
  • Melanoma Research
  • Bei Zhao +2
  • Discussion
  • Citations5

Microenvironment-Driven Resistance to BRAF Inhibition Comes of Age

  • Dec 01, 2015
  • Journal of Investigative Dermatology
  • Dinoop Ravindran Menon +1
  • PDF
  • Research Article
  • Citations25

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.

  • May 27, 2015
  • PloS one
  • Joost C M Uitdehaag +8
  • Preprint Article

Data from The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

  • Mar 31, 2023
  • Nikolas K Haass +7
  • Preprint Article

Data from The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel

  • Mar 31, 2023
  • Nikolas K Haass +7
  • Research Article

Highlights of This Issue

  • Jun 01, 2016
  • Molecular Cancer Therapeutics
  • PDF
  • Research Article
  • Citations28

Altered Expression of Shorter p53 Family Isoforms Can Impact Melanoma Aggressiveness.

  • Oct 18, 2021
  • Cancers
  • Ana Tadijan +11
  • Discussion
  • Citations6

BRAF Inhibitors in Melanoma Management: When Friends Become Foes

  • Dec 03, 2021
  • Journal of Investigative Dermatology
  • Gagan Chhabra +1
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.